Literature DB >> 17855554

Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses.

Zoe Waibler1, Martina Anzaghe, Holger Ludwig, Shizuo Akira, Siegfried Weiss, Gerd Sutter, Ulrich Kalinke.   

Abstract

Modified vaccinia virus Ankara (MVA) is a highly attenuated vaccinia virus strain undergoing clinical evaluation as a replication-deficient vaccine vector against various infections and tumor diseases. To analyze the basis of its high immunogenicity, we investigated the mechanism of how MVA induces type I interferon (IFN) responses. MVA stimulation of bone marrow-derived dendritic cells (DC) showed that plasmacytoid DC were main alpha IFN (IFN-alpha) producers that were triggered independently of productive infection, viral replication, or intermediate and late viral gene expression. Increased IFN-alpha levels were induced upon treatment with mildly UV-irradiated MVA, suggesting that a virus-encoded immune modulator(s) interfered with the host cytokine response. Mice devoid of Toll-like receptor 9 (TLR9), the receptor for double-stranded DNA, mounted normal IFN-alpha responses upon MVA treatment. Furthermore, mice devoid of the adaptors of TLR signaling MyD88 and TRIF and mice deficient in protein kinase R (PKR) showed IFN-alpha responses that were only slightly reduced compared to those of wild-type mice. MVA-induced IFN-alpha responses were critically dependent on autocrine/paracrine triggering of the IFN-alpha/beta receptor and were independent of IFN-beta, thus involving "one-half" of a positive-feedback loop. In conclusion, MVA-mediated type I IFN secretion was primarily triggered by non-TLR molecules, was independent of virus propagation, and critically involved IFN feedback stimulation. These data provide the basis to further improve MVA as a vaccine vector.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17855554      PMCID: PMC2168990          DOI: 10.1128/JVI.01190-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence.

Authors:  H Meyer; G Sutter; A Mayr
Journal:  J Gen Virol       Date:  1991-05       Impact factor: 3.891

2.  Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line.

Authors:  M W Carroll; B Moss
Journal:  Virology       Date:  1997-11-24       Impact factor: 3.616

3.  [The effectiveness of immunization with vaccinia virus type "MVA" against an infection with cowpox virus type "OPV 85" in rabbits].

Authors:  E Munz; S Linckh; I C Renner-Müller; M Reimann
Journal:  Zentralbl Veterinarmed B       Date:  1993-03

4.  Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type II TNF receptor.

Authors:  F Q Hu; C A Smith; D J Pickup
Journal:  Virology       Date:  1994-10       Impact factor: 3.616

5.  A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.

Authors:  G Sutter; L S Wyatt; P L Foley; J R Bennink; B Moss
Journal:  Vaccine       Date:  1994-08       Impact factor: 3.641

6.  TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function.

Authors:  Anne Krug; Anthony R French; Winfried Barchet; Jens A A Fischer; Andrzej Dzionek; Jeanette T Pingel; Michael M Orihuela; Shizuo Akira; Wayne M Yokoyama; Marco Colonna
Journal:  Immunity       Date:  2004-07       Impact factor: 31.745

7.  Nonreplicating vaccinia vector efficiently expresses recombinant genes.

Authors:  G Sutter; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

8.  Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling.

Authors:  O R Colamonici; P Domanski; S M Sweitzer; A Larner; R M Buller
Journal:  J Biol Chem       Date:  1995-07-07       Impact factor: 5.157

9.  Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity.

Authors:  A Alcamí; G L Smith
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

10.  Functional role of type I and type II interferons in antiviral defense.

Authors:  U Müller; U Steinhoff; L F Reis; S Hemmi; J Pavlovic; R M Zinkernagel; M Aguet
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

View more
  51 in total

1.  Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Authors:  Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.

Authors:  Meike S Gratz; Yasemin Suezer; Melanie Kremer; Asisa Volz; Monir Majzoub; Kay-Martin Hanschmann; Ulrich Kalinke; Astrid Schwantes; Gerd Sutter
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

3.  Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA.

Authors:  Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

4.  In vivo imaging of inflammasome activation reveals a subcapsular macrophage burst response that mobilizes innate and adaptive immunity.

Authors:  Pervinder Sagoo; Zacarias Garcia; Beatrice Breart; Fabrice Lemaître; David Michonneau; Matthew L Albert; Yves Levy; Philippe Bousso
Journal:  Nat Med       Date:  2015-12-21       Impact factor: 53.440

Review 5.  Translational Mini-Review Series on Vaccines for HIV: Harnessing innate immunity for HIV vaccine development.

Authors:  E G Rhee; D H Barouch
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

6.  Human plasmacytoid dendritic cell accumulation amplifies their type 1 interferon production.

Authors:  Anne P Liao; Mohammad Salajegheh; Chris Morehouse; Remedios Nazareno; Ronald G Jubin; Bahija Jallal; Yihong Yao; Steven A Greenberg
Journal:  Clin Immunol       Date:  2010-03-25       Impact factor: 3.969

7.  Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components.

Authors:  Zoe Waibler; Martina Anzaghe; Theresa Frenz; Astrid Schwantes; Christopher Pöhlmann; Holger Ludwig; Marcos Palomo-Otero; Antonio Alcamí; Gerd Sutter; Ulrich Kalinke
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

8.  Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms.

Authors:  Maryam Ahmed; Latoya M Mitchell; Shelby Puckett; Kristina L Brzoza-Lewis; Douglas S Lyles; Elizabeth M Hiltbold
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

9.  Conventional bone marrow-derived dendritic cells contribute to toll-like receptor-independent production of alpha/beta interferon in response to inactivated parapoxvirus ovis.

Authors:  Sabine Siegemund; Andrea Hartl; Heiner von Buttlar; Franziska Dautel; Rüdiger Raue; Marina A Freudenberg; György Fejer; Mathias Büttner; Gabriele Köhler; Carsten J Kirschning; Tim Sparwasser; Gottfried Alber
Journal:  J Virol       Date:  2009-07-01       Impact factor: 5.103

10.  Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor.

Authors:  Eva Calvo-Pinilla; Teresa Rodríguez-Calvo; Juan Anguita; Noemí Sevilla; Javier Ortego
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.